Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +36.43%
#3 MetaDAO MetaDAO +28.82%
#4 Rain Rain +23.15%
#5 Bedrock Bedrock +18.87%
#6 Pons Pons +18.81%
#7 Prom Prom +18.28%
#8 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +17.63%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +17.19%
#10 Ontology Gas Ontology Gas +15.31%
Coin of the day
QuantixAI QuantixAI
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc.

GRCL
Rankning i aktier #20198
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company... Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
Aktiekurs
$10.25
Senast synkroniserad: 2024-02-22
Marknadsvärde
$137.83M
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
CN
Handel Gracell Biotechnologies Inc. (GRCL)

Kategori

Healthcare
Aktiekurshistorik för Gracell Biotechnologies Inc. (GRCL)
Högsta slutkurs: $10.24 den 2024-02-01

Lägsta slutkurs: $22.88 den 2021-01-01
Aktiekurshistorik för Gracell Biotechnologies Inc. från 2021 till 2026
Årlig aktiekursutveckling
År Prestanda
2024 60.59%
2023 155.25%
2022 -61.61%
2021 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 50.56%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 525.80%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.47 -12.71%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $772.27 8.67%
CH